NCT02254018View on ClinicalTrials.gov

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 1, 2002

Primary Completion Date

February 1, 2005

Conditions
Head and Neck Neoplasms
Interventions
DRUG

bivatuzumab mertansine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY